[Bromazepam(Lexotan) and chlorprothixene(Taractan) in psychoneurotic anxiety states. A randomized, double-blind study from general practice concerning the effect, drug consumption, and risk of repeated treatment].
D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D001960:Bromazepam / Q000009:adverse effects / Q000627:therapeutic use*; D002749:Chlorprothixene / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D011897:Random Allocation
D014151:Anti-Anxiety Agents; D002749:Chlorprothixene; D001960:Bromazepam
Bromazepam(Lexotan) og klorprotiksen (Taractan) ved akutte Psykoneurotiske angsttilstande. En randomiseret, dobbeltblind undersøgelse fra almen praksis med henblik på effekt, laegemiddelforbrug og risiko for genoptagelse af behandling.